Repligen (RGEN) reported Q2 results before the bell today that surpassed expectations and has the stock up nicely (6% at mid-day) and bucking the broader market weakness. Revenue was up 86% to $163 million, beating by nearly $19 million, while adjusted EPS of $0.79 by...
Read More
Accolade (ACCD) reported Q1 fiscal 2022 results after the bell yesterday that beat on the top line and missed on the bottom line. Revenue was up 66% to $59.5 million (beating by $3.7 million) while adjusted EPS of -$0.87 missed by $0.47. Management raised guidance...
Read More
Yesterday I mentioned that I would follow up today with notes from the Thunderbird Entertainment (TBRD.CA, THBRF) earnings call. Here are a few tidbits from that call.
Read More
Porch Group (PRCH) Reports Q1
Read More
BioLife Solutions (BLFS) reported yesterday afternoon and Q1 results beat expectations. Revenue was up 38.6% to $16.9 million (beating by $800K) while adjusted EPS of $0.01 beat by a penny. Management also bumped up full-year guidance, with revenue now expected in the $106 to million...
Read More
EVBG, KRNT and CRNC Report. Sell GSHD and CDLX
Read More
After yesterday’s bloodbath in growth stocks, today feels pretty good. We may be able to thank a downright terrible April jobs number this morning (266,000 added versus expectation of 1 million), which may have temporarily quelled concerns over rising rates.
Read More
This week feels a lot like March. In other words, it’s pretty awful for growth stocks both big and small. The positive momentum from April has seemingly evaporated. There’s no sugar coating it – we’re taking a hit this week. The chatter around rates...
Read More
Cardlytics (CDLX) reported last night that Q1 revenue grew by 17% to $53.2 million (beating by $2 million) and that adjusted EPS came in at -$0.34, a drop from -$0.26 in the year ago quarter (and $0.03 shy of expectations). Overall, the quarter showed improvement...
Read More
The market has been a little iffy over the last five or so sessions. This action, coming on the back of great earnings from mega cap tech stocks last week, but not great reactions, suggests a more conservative stance is appropriate right now some...
Read More
Goosehead Insurance (GSHD) reported after the close yesterday that Q1 revenue rose by 53% to $31.2 million (beating by $2.5 million) and adjusted EPS rose to $0.03 from $0.01 in the year-ago quarter (missing by $0.03). That pace of revenue growth was up from in...
Read More
Porch Group (PRCH) has been very weak recently and moves to hold today. This move hasn’t been unique to PRCH, in fact most SPAC IPOs have been soft for a while now. However, we saw a sizeable decline on Friday and follow-through softness today.
Read More
Porch (PRCH) reported its first quarter as a public company this week. The numbers are a little messy due to divestments and acquisitions over the last year, but the bottom line is that the quarter was good and the company is well-positioned for the ahead...
Read More
The market continues to be extremely challenging for growth-oriented stocks and many of our names are trading near support levels. It’s one of those environments where, with many stocks down 20% to 40% from their highs, it’s an entirely “normal,” albeit significant, correction. other...
Read More
Accolade revealed preliminary Q4 and full-year 2020 results after the bell yesterday and announced a private offering of $250 million convertible notes, with a $37.5 million option (pricing to be determined). The reasons for the offering are the usual – working capital, acquisitions, investments...
Read More
BioLife (BLFS) reported Q4 results yesterday after the close that surpassed revenue expectations. Revenue was up 77.5% to $14.7 million (beating by $1.2 million) while adjusted EPS of -$0.01 was in-line. For the full-year 2020 revenue was up 76% to $48.1 million, driven largely Media...
Read More
With so much going on in the market I wanted to share some of what’s running through my head today, then keep tomorrow’s Weekly Update focused mostly on stock updates.
Read More
Suffice to say the last two weeks have been very tough. On the one hand, yes, of course some sort of correction or pullback has been expected given the huge progress the market – and growth stocks, small caps and IPOs in particular have...
Read More
Arena Pharmaceuticals (ARNA) yesterday announced that olorinab failed to meet the primary endpoint in the Phase 2 CAPTIVATE study in IBS abdominal pain. This is disappointing but not remotely the reason to own (or sell) the stock. IBS is a difficult to treat condition when...
Read More
Cardlytics (CDLX) reported Q4 2020 numbers this morning that surpassed revenue expectations by roughly 10% and missed modestly on earnings. Revenue was down 3.2% to $67.1 million (beating by $6.2 million) while adjusted EPS of -$0.05 missed by $0.02. Management gave 2021 guidance that for...
Read More
Call Financial Freedom Federation Customer Service at
(800) 777-2658